Peptide Comparison
BPC-157 vs Wolverine
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
BPC-157 has stronger documented evidence (Anecdotal + Animal Studies) than Wolverine (Anecdotal) while both occupy the tissue-repair class. When clinical-evidence tier is the deciding factor, BPC-157 is the safer pick. Wolverine may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| BPC-157 | Wolverine | |
|---|---|---|
| Class | Synthetic pentadecapeptide; cytoprotective | Combination peptide stack |
| Drug class | Tissue Repair | Tissue Repair |
| Mechanism | Promotes angiogenesis via VEGFR2 [1]; upregulates growth factors [1]; modulates NO and dopamine pathways [1]; stabilizes gut barrier [1] | Combined cytoprotective + actin regulation (see individual entries) |
| Route | SC / IM / Oral / Intranasal | SC / IM |
| Half-life | less than 30 min (IV and IM in rats and dogs; oral not measured) | See individual peptides |
| Dosage (research) | 250 mcg SC 2x daily near injury (Seeds Vol 1 starting dose, common upper bound 500 mcg per dose); 250 mcg oral 2x daily | BPC 250-500 mcg + TB 2 mg SC daily or split weekly |
| Evidence tier | Anecdotal + Animal Studies | Anecdotal |
| Research depth | 190 indexed | 1 indexed |
| Availability | Compounding Restricted | Compounding Restricted |
| Reported risks | Limited human trials [1]; injection site irritation; theoretical pro-angiogenic/tumor concerns [1] | Combined risk profile of both; no combination safety trials |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick BPC-157 or Wolverine?
BPC-157 has stronger documented evidence (Anecdotal + Animal Studies) than Wolverine (Anecdotal) while both occupy the tissue-repair class. When clinical-evidence tier is the deciding factor, BPC-157 is the safer pick. Wolverine may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between BPC-157 and Wolverine?
BPC-157 is classed as Synthetic pentadecapeptide; cytoprotective; Wolverine is classed as Combination peptide stack. Reported mechanism: BPC-157, Promotes angiogenesis via VEGFR2; upregulates growth factors; modulates NO and dopamine pathways; stabilizes gut barrier; Wolverine, Combined cytoprotective + actin regulation (see individual entries). Reported half-life: BPC-157, less than 30 min (IV and IM in rats and dogs; oral not measured); Wolverine, See individual peptides. Routes in published studies: BPC-157, SC / IM / Oral / Intranasal; Wolverine, SC / IM.
Which has stronger evidence, BPC-157 or Wolverine?
BPC-157 and Wolverine sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. BPC-157 is graded Anecdotal + Animal Studies, with 9 cited sources on its reference page and 190 indexed studies. Wolverine is graded Anecdotal, with 2 cited sources on its reference page and 1 indexed studies.
Which is more accessible, BPC-157 or Wolverine?
Neither BPC-157 nor Wolverine is an FDA-approved drug. Catalog status: BPC-157, Compounding Restricted; Wolverine, Compounding Restricted. FDA's Pharmacy Compounding Advisory Committee voted 8 for, 6 against, 1 abstention on 23 July 2026 to recommend BPC-157 for the 503A Bulks List; the vote is advisory and changes nothing by itself.
Are BPC-157 and Wolverine ever combined?
BPC-157 and Wolverine appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…